← Leaderboards
Magdy H Selim
Beth Israel Deaconess Medical Center
$25,483,621
Attributed
$28,966,383
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.4M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,966,383 · 6
By mechanism
U01$22,895,668 · 3
UF1$2,705,364 · 1
UG3$2,336,853 · 1
R01$1,028,498 · 1
Top collaborators
- Ashkan Shoamanesh5 shared
- J Duffy Mocco1 shared
- Sharon Dziuba Yeatts1 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Ashkan Shoamanesh$1,924,861
Others in their field
Top investigators on “Cerebral Hemisphere Hemorrhage”
- Daniel Woo · University Of Cincinnati$47,901,065
- Daniel F Hanley · Johns Hopkins University$46,218,160
- Shunichi Homma · Columbia University Health Sciences$24,561,164
- Joseph Paul Broderick · University Of Cincinnati$22,520,549
- Jeffrey L Saver · University Of California Los Angeles$22,299,632
- Adnan Iqbal Qureshi · Univ Of Med/Dent Of Nj-Nj Medical School$18,127,351
Research focus
Cerebral Hemisphere HemorrhageRandomizedProspectiveUnited States National Institutes Of HealthOpen LabelDisabilityIncidenceBrain HemorrhageSafetyPhase Iii Clinical TrialsAmericanBiological MarkersBrainCessation Of LifeCognitiveCognitive TestingHemorrhageFunctional OutcomesLobarPublic HealthAreaHigh RiskCardiovascular SystemFollow-Up
Grant awards (19)
StATins Use in intRacerebral hemorrhage patieNts (SATURN)$2,928,100
U01 · FY2025 · NS · contact PI
Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation (MINUTE) Trial$2,336,853
UG3 · FY2025 · NS
StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study$1,000,459
U01 · FY2025 · NS · contact PI
StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study$68,553
U01 · FY2025 · NS · contact PI
StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study$41,552
U01 · FY2025 · NS · contact PI
StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study$33,793
U01 · FY2025 · NS · contact PI
StATins Use in intRacerebral hemorrhage patieNts (SATURN)$558,431
U01 · FY2024 · NS · contact PI
StATins Use in intRacerebral hemorrhage patieNts (SATURN)$3,150,398
U01 · FY2022 · NS · contact PI
StATins Use in intRacerebral hemorrhage patieNts (SATURN)$3,398,290
U01 · FY2021 · NS · contact PI
StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study$2,705,364
UF1 · FY2021 · NS · contact PI
StATins Use in intRacerebral hemorrhage patieNts (SATURN)$3,014,650
U01 · FY2019 · NS · contact PI
Futility Study of Deferoxamine Mesylate in Intracerebral Hemorrhage (i-DEF)$1,456,455
U01 · FY2016 · NS · contact PI
Futility Study of Deferoxamine Mesylate in Intracerebral Hemorrhage (i-DEF)$1,744,825
U01 · FY2015 · NS · contact PI
Futility Study of Deferoxamine Mesylate in Intracerebral Hemorrhage (i-DEF)$1,934,834
U01 · FY2014 · NS · contact PI
Futility Study of Deferoxamine Mesylate in Intracerebral Hemorrhage (Hi-DEF)$2,193,084
U01 · FY2013 · NS · contact PI
Futility Study of Deferoxamine Mesylate in Intracerebral Hemorrhage (Hi-DEF)$1,372,244
U01 · FY2012 · NS · contact PI
Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage$184,238
R01 · FY2010 · NS · contact PI
Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage$382,261
R01 · FY2009 · NS · contact PI
Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage$461,999
R01 · FY2008 · NS · contact PI